Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJuly 5, 2017	Minerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares WALTHAM, Mass. , July 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced public offering of 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the	View HTML Minerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 22.7 KB
Toggle SummaryDecember 3, 2014	Minerva Neurosciences Announces Completion of Development and Final Selection of Once-Daily Dose Formulation of MIN-101 for Its Schizophrenia Program New Formulation to be Used in Planned Phase 2b Clinical Trial Has Been Developed to Offer Improved Safety, Tolerability and Pharmacokinetic Profile	View HTML Minerva Neurosciences Announces Completion of Development and Final Selection of Once-Daily Dose Formulation of MIN-101 for Its Schizophrenia Program 21.5 KB
Toggle SummarySeptember 22, 2014	Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial Bioavailability Study in U.S. for Investigational Therapy in Development for Treatment of Insomnia to be Initiated	View HTML Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial 19.7 KB
Toggle SummaryFebruary 5, 2020	Minerva Neurosciences Announces Completion of Patient Enrollment in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia Data readout expected in the second quarter of 2020 WALTHAM, Mass. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of central	View HTML PDF Version
Toggle SummaryFebruary 22, 2016	Minerva Neurosciences Announces Completion of Patient Enrollment in Phase IIa Trial of MIN-117 in Major Depressive Disorder	View HTML Minerva Neurosciences Announces Completion of Patient Enrollment in Phase IIa Trial of MIN-117 in Major Depressive Disorder 19 KB
Toggle SummaryJanuary 6, 2020	Minerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia Top-line results expected in the second quarter of 2020 WALTHAM, Mass. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of central	View HTML PDF Version
Toggle SummaryJuly 24, 2017	Minerva Neurosciences Announces Departure of Directors WALTHAM, Mass. , July 24, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the resignation of two members of its board of directors,	View HTML Minerva Neurosciences Announces Departure of Directors 17.3 KB
Toggle SummarySeptember 5, 2017	Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder WALTHAM, Mass. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the enrollment of the first patient in a Phase 2b	View HTML PDF Version
Toggle SummaryDecember 21, 2017	Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder WALTHAM, Mass. , Dec. 21, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the enrollment of the first patient in a Phase 2b	View HTML PDF Version
Toggle SummaryDecember 6, 2017	Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder WALTHAM, Mass. , Dec. 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the enrollment of the first patient in a Phase 2b	View HTML PDF Version

Press Releases

Shareholder Tools